The majority of insurers will soon be publishing their first Solvency and Financial Condition Report (SFCR). We take a look at the SFCR’s published by firms with non-December year-ends and highlight lessons to be learnt.
Our annual investment conference took place in January, with our much anticipated keynote speaker, Alastair Campbell, sharing his views on current political themes, all of which will be the major force on investment markets during 2017.
Our annual report on with-profits investment performance and strategy contains information on one-year returns over 2015 and trends in asset allocations. This blog focusses on the three-year performance figures to best judge funds on their performance.
EIOPA is not expected to offer any further clarity in terms of applying proportionality to the principle of look-through of assets. Scott Eason looks at a recent Investment Association seminar to see what other European practitioners are doing.
Just when life insurers were breathing a sigh of relief for getting over the Matching Adjustment (MA) hurdle, the Prudential Regulation Authority (PRA) has released a draft supervisory statement explaining further aspects of how they expect portfolios to be managed.
In his introduction to the FCA’s Business Plan 2016/17, the Chairman uses the phrase “constructive deterrence” - this phrase may help insurers and distributors to understand the overall philosophy of the FCA but will it lead to better customer outcomes?
Scott Eason and Michael Henderson explore the potential implications of the PRA’s announcement to undertake a review of Equity Release Mortgages.
With the Solvency II implementation date looming, firms must make sure their processes are ready to meet the requirements. We explore how a standard formula Solvency Capital Requirement calculation tool can be made as simple as possible for the end user.
Further to last year’s consultation, the PRA has now introduced measures that may lead to financial penalties on actuaries that fail to observe PRA rules or the requirement to 'whistleblow' under FSMA.